Surgery Partners (NASDAQ:SGRY) Insider Jennifer Baldock Sells 10,082 Shares of Stock

Surgery Partners, Inc. (NASDAQ:SGRY) insider Jennifer Baldock sold 10,082 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $13.70, for a total transaction of $138,123.40. Following the transaction, the insider owned 332,272 shares of the company’s stock, valued at approximately $4,552,126.40. This represents a 2.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Surgery Partners Trading Down 0.4%

SGRY opened at $13.30 on Tuesday. The firm’s fifty day moving average is $15.16 and its two-hundred day moving average is $18.00. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87. The firm has a market cap of $1.72 billion, a PE ratio of -21.45 and a beta of 1.95. Surgery Partners, Inc. has a twelve month low of $12.25 and a twelve month high of $24.60.

Surgery Partners (NASDAQ:SGRY) last announced its quarterly earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The firm had revenue of $885.00 million for the quarter, compared to the consensus estimate of $866.54 million. During the same period in the prior year, the business earned $0.44 earnings per share. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. Equities research analysts anticipate that Surgery Partners, Inc. will post 0.67 EPS for the current year.

Surgery Partners announced that its Board of Directors has approved a stock buyback program on Thursday, February 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to buy up to 9.7% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a report on Wednesday, March 4th. Jefferies Financial Group reiterated a “buy” rating on shares of Surgery Partners in a report on Wednesday, March 4th. Mizuho decreased their price objective on Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. Royal Bank Of Canada lowered their target price on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday, March 4th. Finally, Barclays dropped their target price on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Surgery Partners presently has an average rating of “Moderate Buy” and an average target price of $24.45.

Surgery Partners News Summary

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

Institutional Trading of Surgery Partners

Several hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC lifted its holdings in shares of Surgery Partners by 3.8% in the fourth quarter. Janus Henderson Group PLC now owns 13,537,984 shares of the company’s stock valued at $209,162,000 after purchasing an additional 501,401 shares in the last quarter. Pentwater Capital Management LP grew its holdings in shares of Surgery Partners by 66.9% during the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock worth $252,777,000 after buying an additional 4,681,000 shares in the last quarter. UBS Group AG grew its holdings in shares of Surgery Partners by 111.4% during the fourth quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after buying an additional 4,113,052 shares in the last quarter. Vanguard Group Inc. raised its position in Surgery Partners by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 7,614,514 shares of the company’s stock valued at $164,778,000 after buying an additional 424,518 shares during the last quarter. Finally, King Street Capital Management L.P. raised its position in Surgery Partners by 24.5% in the 2nd quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company’s stock valued at $138,382,000 after buying an additional 1,225,000 shares during the last quarter.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.